Patients on oral bisphosphonate therapy can be successfully treated with implant surgery, when minimum values of [-terminal cross-linked telopeptide type I collagen (CTX) are
**Core Concept**
The underlying principle being tested is the management of patients on oral **bisphosphonate** therapy who are undergoing **implant surgery**. This involves understanding the role of **bone turnover markers** like **C-terminal cross-linked telopeptide type I collagen (CTX)** in assessing the risk of **bisphosphonate-related osteonecrosis of the jaw (BRONJ)**.
**Why the Correct Answer is Right**
To minimize the risk of BRONJ, patients on bisphosphonates should have their bone turnover markers assessed before implant surgery. A CTX level is used as a marker of bone resorption. The correct answer choice should reflect the minimum CTX value that indicates a lower risk of BRONJ, thus allowing for safe implant placement.
**Why Each Wrong Option is Incorrect**
**Option A:** This choice is incorrect because it does not reflect the established threshold for safe implant surgery in patients on bisphosphonates.
**Option B:** Similarly, this option does not align with clinical guidelines for the management of patients on bisphosphonate therapy undergoing implant surgery.
**Option C:** This choice is also incorrect as it does not represent the minimum CTX value recommended for proceeding with implant surgery.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that the management of patients on bisphosphonates requires careful assessment of their bone health to prevent complications like BRONJ. Monitoring **CTX levels** is crucial in this process.
**Correct Answer:** D. 150 pg/mL